{
    "ticker": "CNTX",
    "name": "Context Therapeutics Inc.",
    "description": "Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women\u2019s cancers. Founded in 2015, the company is committed to addressing significant unmet medical needs in oncology, particularly in breast and gynecological cancers. Context Therapeutics is pioneering the use of its novel, proprietary drug candidates that target the tumor microenvironment and immune system to enhance therapeutic efficacy. The company's lead product candidate, ON-12380, is a selective oral estrogen receptor modulator designed to inhibit tumor growth in hormone receptor-positive breast cancer. Context Therapeutics is also advancing its pipeline with additional therapeutic candidates that leverage the latest advancements in cancer biology. The company emphasizes a collaborative approach, working closely with academic institutions and industry partners to drive its research and development efforts. With a mission to improve treatment options and outcomes for women with cancer, Context Therapeutics is dedicated to translating scientific discoveries into meaningful therapies. The firm is actively engaged in clinical trials to evaluate the safety and efficacy of its treatments, with the goal of bringing new hope to patients facing challenging diagnoses.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Philadelphia, Pennsylvania, USA",
    "founded": "2015",
    "website": "https://www.contexttherapeutics.com",
    "ceo": "Martin Lehr",
    "social_media": {
        "twitter": "https://twitter.com/ContextThera",
        "linkedin": "https://www.linkedin.com/company/context-therapeutics/"
    },
    "investor_relations": "https://www.contexttherapeutics.com/investors/",
    "key_executives": [
        {
            "name": "Martin Lehr",
            "position": "CEO"
        },
        {
            "name": "David S. F. W. P. G. Leung",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ON-12380"
            ]
        }
    ],
    "seo": {
        "meta_title": "Context Therapeutics Inc. | Innovative Therapies for Women\u2019s Cancers",
        "meta_description": "Learn about Context Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for women\u2019s cancers, including breast and gynecological cancers.",
        "keywords": [
            "Context Therapeutics",
            "Women\u2019s Cancers",
            "Breast Cancer",
            "Biotechnology",
            "ON-12380"
        ]
    },
    "faq": [
        {
            "question": "What is Context Therapeutics focused on?",
            "answer": "Context Therapeutics is focused on developing innovative therapies for women\u2019s cancers, including breast and gynecological cancers."
        },
        {
            "question": "Who is the CEO of Context Therapeutics?",
            "answer": "Martin Lehr is the CEO of Context Therapeutics Inc."
        },
        {
            "question": "Where is Context Therapeutics headquartered?",
            "answer": "Context Therapeutics is headquartered in Philadelphia, Pennsylvania, USA."
        },
        {
            "question": "What is the lead product candidate of Context Therapeutics?",
            "answer": "The lead product candidate is ON-12380, a selective oral estrogen receptor modulator."
        },
        {
            "question": "When was Context Therapeutics founded?",
            "answer": "Context Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "CLVS",
        "FGEN",
        "ZIOP",
        "CYTK"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "AVEO",
        "NVS"
    ]
}